KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Sales and Divestitures (2016 - 2017)

Neogenomics filings provide 6 years of Gains from Sales and Divestitures readings, the most recent being $182744.0 for Q4 2017.

  • On a quarterly basis, Gains from Sales and Divestitures rose 452.38% to $182744.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $182744.0, a 452.38% increase, with the full-year FY2017 number at $182744.0, up 452.38% from a year prior.
  • Gains from Sales and Divestitures hit $182744.0 in Q4 2017 for Neogenomics, up from $33083.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $182744.0 in Q4 2017 to a low of $12820.0 in Q4 2015.
  • Median Gains from Sales and Divestitures over the past 5 years was $32000.0 (2013), compared with a mean of $55754.4.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 43.36% in 2014 and later skyrocketed 452.38% in 2017.
  • Neogenomics' Gains from Sales and Divestitures stood at $32000.0 in 2013, then crashed by 43.36% to $18125.0 in 2014, then dropped by 29.27% to $12820.0 in 2015, then soared by 158.06% to $33083.0 in 2016, then skyrocketed by 452.38% to $182744.0 in 2017.
  • The last three reported values for Gains from Sales and Divestitures were $182744.0 (Q4 2017), $33083.0 (Q4 2016), and $12820.0 (Q4 2015) per Business Quant data.